Literature DB >> 27698062

Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor Enhance Angiotensin II-Induced Renal Vascular Sensitivity and Reduce Renal Function During Pregnancy.

Mark W Cunningham1, Jan M Williams1, Lorena Amaral1, Nathan Usry1, Gerd Wallukat1, Ralf Dechend1, Babbette LaMarca2.   

Abstract

Preeclamptic women produce agonistic autoantibodies to the angiotensin II type 1 receptor (AT1-AA) and exhibit increased blood pressure (mean arterial pressure), vascular sensitivity to angiotensin II (ANG II), and display a decrease in renal function. The objective of this study was to examine the renal hemodynamic changes during pregnancy in the presence of AT1-AAs with or without a slow pressor dose of ANG II. In this study, mean arterial pressure was elevated in all pregnant rats treated with ANG II with or without AT1-AA. Glomerular filtration rate was reduced from 1.90±0.16 mL/min in normal pregnant (NP) to 1.20±0.08 in ANG II+AT1-AA rats. Renal blood flow was decreased in ANG II+AT1-AA versus NP rats to 7.4±1.09 versus 15.4±1.75 mL/min. Renal vascular resistance was drastically increased between ANG II+AT1-AA versus NP rats (18.4±2.91 versus 6.4±0.77 mm Hg/mL per minute). Isoprostane excretion was increased by 3.5-fold in ANG II+AT1-AA versus NP (1160±321 versus 323±52 pg/mL). In conclusion, ANG II and AT1-AA together significantly decrease glomerular filtration rate by 37% and renal blood flow by 50% and caused a 3-fold increase in renal vascular resistance and isoprostane levels versus NP rats. These data indicate the importance of AT1-AAs to enhance ANG II-induced renal vasoconstriction and reduce renal function as mechanisms to cause hypertension as observed during preeclampsia.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  angiotensin II; autoantibodies; hypertension; preeclampsia; pregnancy

Mesh:

Substances:

Year:  2016        PMID: 27698062      PMCID: PMC5142826          DOI: 10.1161/HYPERTENSIONAHA.116.07971

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  49 in total

Review 1.  Role of the renin-angiotensin system in the pathogenesis of preeclampsia.

Authors:  Dinesh M Shah
Journal:  Am J Physiol Renal Physiol       Date:  2005-04

Review 2.  Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia.

Authors:  Ralf Dechend; Volker Homuth; Gerd Wallukat; Dominik N Müller; Manja Krause; Joachim Dudenhausen; Hermann Haller; Friedrich C Luft
Journal:  J Soc Gynecol Investig       Date:  2006-02

3.  Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia.

Authors:  Vasyl Holobotovskyy; Yee Seng Chong; Jennifer Burchell; Bo He; Michael Phillips; Leo Leader; Timothy V Murphy; Shaun L Sandow; Douglas J McKitrick; Adrian K Charles; Marianne Tare; Leonard F Arnolda; Ruth Ganss
Journal:  Sci Transl Med       Date:  2015-06-03       Impact factor: 17.956

4.  Angiotensin II receptor type 1 autoantibodies promote endothelial microparticles formation through activating p38 MAPK pathway.

Authors:  Shijun Yang; Qi Zhong; Zhihua Qiu; Xiao Chen; Fen Chen; Khamis Mustafa; Dan Ding; Yanzhao Zhou; Jibin Lin; Sen Yan; Yihuan Deng; Min Wang; Yingling Zhou; Yuhua Liao; Zihua Zhou
Journal:  J Hypertens       Date:  2014-04       Impact factor: 4.844

5.  Plasma volume and glomerular filtration rate in pregnancy and their relation to differences in fetal growth.

Authors:  H M Gibson
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-12

Review 6.  Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension.

Authors:  Florian Herse; Babbette LaMarca
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

7.  Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness.

Authors:  S AbdAlla; H Lother; A el Massiery; U Quitterer
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

8.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.

Authors:  Babbette LaMarca; Marc Parrish; Lillian Fournier Ray; Sydney R Murphy; Lyndsay Roberts; Porter Glover; Gerd Wallukat; Katrin Wenzel; Kathy Cockrell; James N Martin; Michael J Ryan; Ralf Dechend
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

Review 10.  Preeclampsia: long-term consequences for vascular health.

Authors:  Lorena M Amaral; Mark W Cunningham; Denise C Cornelius; Babbette LaMarca
Journal:  Vasc Health Risk Manag       Date:  2015-07-15
View more
  18 in total

Review 1.  Residual vascular dysfunction in women with a history of preeclampsia.

Authors:  Anna E Stanhewicz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-22       Impact factor: 3.619

2.  Tumor necrosis factor alpha (TNF-α) blockade improves natural killer cell (NK) activation, hypertension, and mitochondrial oxidative stress in a preclinical rat model of preeclampsia.

Authors:  Mark W Cunningham; Aswathi Jayaram; Evangeline Deer; Lorena M Amaral; Venkata Ramana Vaka; Tarek Ibrahim; Denise C Cornelius; Babbette LaMarca
Journal:  Hypertens Pregnancy       Date:  2020-07-10       Impact factor: 2.108

3.  Local angiotensin-(1-7) administration improves microvascular endothelial function in women who have had preeclampsia.

Authors:  Anna E Stanhewicz; Lacy M Alexander
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-10-02       Impact factor: 3.619

4.  Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia.

Authors:  Anna E Stanhewicz; Sandeep Jandu; Lakshmi Santhanam; Lacy M Alexander
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

5.  AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats.

Authors:  Mark W Cunningham; Javier Castillo; Tarek Ibrahim; Denise C Cornelius; Nathan Campbell; Lorena Amaral; Venkata Ramana Vaka; Nathan Usry; Jan M Williams; Babbette LaMarca
Journal:  Hypertension       Date:  2018-03-19       Impact factor: 10.190

6.  Sympathetic nervous system control of vascular function and blood pressure during pregnancy and preeclampsia.

Authors:  Frank T Spradley
Journal:  J Hypertens       Date:  2019-03       Impact factor: 4.844

Review 7.  Combined Oral Contraceptive Pill-Induced Hypertension and Hypertensive Disorders of Pregnancy: Shared Mechanisms and Clinical Similarities.

Authors:  Madugodaralalage D S K Gunaratne; Bjorg Thorsteinsdottir; Vesna D Garovic
Journal:  Curr Hypertens Rep       Date:  2021-05-13       Impact factor: 5.369

8.  Endothelial PPARγ (Peroxisome Proliferator-Activated Receptor-γ) Protects From Angiotensin II-Induced Endothelial Dysfunction in Adult Offspring Born From Pregnancies Complicated by Hypertension.

Authors:  Anand R Nair; Sebastiao D Silva; Larry N Agbor; Jing Wu; Pablo Nakagawa; Masashi Mukohda; Ko-Ting Lu; Jeremy A Sandgren; Gary L Pierce; Mark K Santillan; Justin L Grobe; Curt D Sigmund
Journal:  Hypertension       Date:  2019-05-20       Impact factor: 9.897

9.  Increased AT2R expression is induced by AT1R autoantibody via two axes, Klf-5/IRF-1 and circErbB4/miR-29a-5p, to promote VSMC migration.

Authors:  Yan Sun; Yang Li; Meili Wang; Mingming Yue; Lina Bai; Jingwei Bian; Weiwei Hao; Jing Sun; Suli Zhang; Huirong Liu
Journal:  Cell Death Dis       Date:  2020-06-08       Impact factor: 8.469

10.  Lower circulating angiotensin II levels are related to the severity of preeclampsia and its risk as disclosed by a specific bioassay.

Authors:  Alfredo Leaños-Miranda; Francisco Méndez-Aguilar; Carlos José Molina-Pérez; Karla Leticia Ramírez-Valenzuela; Liliana Janet Sillas-Pardo; Navid Claudian Uraga-Camacho; Irma Isordia-Salas; María Guadalupe Berumen-Lechuga
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.